Sep 01, 2020
Strengthened patent protection for arfolitixorin in Japan
Aug 13, 2020
Invitation to a conference call and webcast by Isofol in connection with the entered license agreement with Solasia
Aug 13, 2020
Isofol enters licensing agreement with Solasia to develop and commercialize arfolitixorin in Japan
Jun 03, 2020
Isofol's Rights Issue Oversubscribed
May 14, 2020
Isofol Publishes Prospectus in Connection With the Fully Guaranteed Preferential Rights Issue of Approximately SEK 150 Million
May 07, 2020
Isofol's Board of Directors Resolve on a Fully Guaranteed Preferential Rights Issue of Approximately SEK 150 Million
May 05, 2020
Isofol's Drug Candidate Arfolitixorin Receives Additional Clinical Patent Approval in the United States
Feb 18, 2020
The First Patient Included in Japan in Isofol's Phase 3 AGENT Study
Jan 30, 2020
Isofol Medical: The Phase 1/2a Study ISO-CC-005 is Completed
Jan 30, 2020
Isofol Medical: Over 200 Patients Now Randomized in the Global Phase 3 AGENT Study
Jan 24, 2020
The First Patient Included in Australia in Isofol's Phase 3 AGENT Study
Dec 20, 2019
Patent Approved in Japan for Isofol's Drug Candidate Arfolitixorin
Oct 18, 2019
Isofol Receives Positive Feedback From PMDA in Japan, Expanding Ongoing Global Pivotal Phase 3 AGENT Trial in First Line Metastatic Colorectal Cancer
Sep 12, 2019
Isofol Announces that an Abstract has been Accepted for Presentation at the 2019 ESMO Congress
Aug 15, 2019
Isofol Announces Management Team Evolution With Appointment of Dr. Roger Tell as Chief Medical Officer
Jul 15, 2019
Isofol Announces Recent Advisory Board Meeting Covering Development Plan for Arfolitixorin
Jun 25, 2019
Isofol Receives Clinical Use Patent Approval in the United States for Drug Candidate arfolitixorin
Jun 10, 2019
Isofol Announces Election of Three New Board Members
May 08, 2019
Isofol Reports 58 % Overall Response Rate in Patients with Metastatic Colorectal Cancer in Phase 1/2a Open Label Extension Study with Arfolitixorin
Feb 01, 2019
Isofol Reports All Employees Participate in Newly Created Share Warrant Program